SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: crysball who wrote (1480)10/29/1998 9:03:00 PM
From: yosi s   of 1491
 
Currently tamoxiphen as adjuvent therapy is taken for 5 years.
As for prevention ,time will tell if 5 years is enough or if you get benefit for taking it for ever.

How ever if Pharmos wants to get that indication it will take many thousands of patients and very long follow up. It is much easier to show effectiveness in treating cancer and preventing recurrance, than showing it to prevent cancer in high risk population.

Pharmos is on record to start Human studies in 1999. (Phase 1).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News